# A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)

> **NCT01011998** · PHASE2 · WITHDRAWN · sponsor: **New Mexico Cancer Research Alliance**

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Gleevec (imatinib), valproic acid

## Key facts

- **NCT ID:** NCT01011998
- **Lead sponsor:** New Mexico Cancer Research Alliance
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-09
- **Primary completion:** 2010-06
- **Final completion:** 2010-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to lack of accrual per Center DSMP, with PI concurrence
- **Last updated:** 2011-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01011998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01011998, "A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01011998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*